We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
IBA-Radcal

Download Mobile App




Robotic Platform Offers Diagnosis and Removal of Lung Cancer During Single Surgery

By HospiMedica International staff writers
Posted on 19 May 2022

Lung cancer is among the leading causes of cancer-related death among men and women, and tends to spread quickly. More...

It does not show any symptoms unless it is very advanced, and can silently spread to virtually any part of the body. This makes early screening and treatment critical. Traditionally, when a patient is diagnosed with a suspicious nodule or mass in their lung, they are referred to a pulmonologist, who may perform a lung biopsy to confirm if it is cancerous. If the lung nodule or mass is confirmed to be cancer, the patient may be referred to a thoracic surgeon, who determines if it can be surgically removed. If it can, the patient undergoes another procedure on a separate day that requires additional anesthesia. On average, patients may wait up to three months from the time a nodule or mass is first discovered to when they receive a diagnosis and treatment. Now, a robotic-assisted minimally invasive biopsy platform allows for the diagnosis and removal of a lung cancer mass during one surgery, thus reducing anxiety and unnecessary waiting time for patients.

The Ion Endoluminal Platform by Intuitive Surgical (Silicon Valley, CA, USA) enables the robotic-assisted bronchoscopy procedure by creating a 3D map of the patient’s lungs using a CT scan. The software then generates the safest and most efficient route through the lung to the nodule or mass. Once the route is determined, an ultrathin and ultra-maneuverable catheter is guided to the site of the lung nodule or mass, where it is marked and biopsied with precision and stability. Lymph nodes are also biopsied during the same procedure, using endobronchial ultrasound. The samples are then evaluated on-site. If the lung nodule is determined to be an early-stage cancer, the surgical team uses the same navigational route to mark the area with dye to prepare for its removal. Then, the patient, still asleep, has a second robotic procedure to remove the lung cancer on the same day.

Ion is designed to fit easily into a bronchoscopy suite and integrate with existing technologies. Physical proximity has been taken into account with a design that keeps the surgical team close to the patient’s airways throughout the procedure. Although Ion does not require the use of cone beam CT for nodule biopsy, the system has been designed to be compatible with this technology. Ion leverages existing imaging technologies with radial endobronchial ultrasound (rEBUS), fluoroscopic, virtual, and live views of the lung all unified in a single system. Additionally, Ion’s network connection allows access to system data. The data dashboard utilizes this automatically collected system data and provides it back to the user. The surgical team can see their data in one place. The dashboard provides a detailed view of system utilization and procedure data. The surgical team can view information on their case times, instruments and accessories utilization, the target nodule location in the lung, as well as the size of a lesion.

Related Links:
Intuitive Surgical


Gold Member
SARS‑CoV‑2/Flu A/Flu B/RSV Sample-To-Answer Test
SARS‑CoV‑2/Flu A/Flu B/RSV Cartridge (CE-IVD)
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
IV Therapy Cart
Avalo I.V Therapy Cart
Semi‑Automatic Defibrillator
Heart Save AED (ED300)
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: A smartphone application displays a glucose concentration that was measured using the new sensor (Photo courtesy of Chuchu Chen and Yonghao Fu)

Wearable Device for Diabetics Could Replace Continuous Glucose Monitoring Systems

Monitoring blood glucose is essential for people with diabetes to prevent complications and maintain long-term health. Current continuous glucose monitoring systems require needles inserted under the skin,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.